📢 BioNTech has signed a $250 million deal with Autolus to develop CAR-T assets.
💼 The partnership aims to advance the development of next-generation CAR-T cell therapies.
🔬 BioNTech will contribute its mRNA manufacturing platform, while Autolus will provide its T-cell receptor technology.
💪 This collaboration will help accelerate the development of innovative cancer treatments.
💼 The partnership aims to advance the development of next-generation CAR-T cell therapies.
🔬 BioNTech will contribute its mRNA manufacturing platform, while Autolus will provide its T-cell receptor technology.
💪 This collaboration will help accelerate the development of innovative cancer treatments.
📢 BioNTech and Autolus Join Forces for Cutting-Edge CAR-T Cancer Therapies
Introduction:
BioNTech has entered into a $250 million collaboration agreement with Autolus to develop next-generation CAR-T cell therapies. The collaboration will focus on advancing Autolus’ CAR-T assets using BioNTech’s mRNA-based technology.
Main points:
- The collaboration between BioNTech and Autolus aims to develop next-generation CAR-T cell therapies.
- BioNTech will provide its mRNA-based technology to advance Autolus’ CAR-T assets.
- The collaboration will focus on developing new CAR-T therapies for solid tumors.
- The upfront payment for the collaboration is $180 million, with potential milestone payments of up to $60 million.
- The collaboration demonstrates the potential of mRNA-based technology in developing innovative cell therapies.
Conclusion:
The collaboration between BioNTech and Autolus represents a significant advancement in the field of cell therapies, particularly for solid tumors. By leveraging BioNTech’s mRNA-based technology, Autolus has the potential to develop more effective and targeted CAR-T cell therapies. This collaboration highlights the growing importance of mRNA-based technology in the biotechnology industry and its potential to revolutionize the field of cell therapies.
